The latest developments across longevity science, biotech, companies and markets. Every item is attributed to an identified source. Scientific evidence context and a LONGEFI Signal are shown when they exist.
Biogen's Phase 2 CELIA trial of diranersen in early Alzheimer's disease demonstrated cognitive benefits and robust tau pathology reduction at 18 months, supporting plans for Phase 3 development despite missing its primary dose-response endpoint.
ReadDevelopment preview only — these items are not published LONGEFI News.
Researchers applied short, repeated pulses of reprogramming factors to aged mice and reported faster muscle and liver repair after injury. Tissue-level markers of…
A locally delivered senolytic maintained vision gains at 36 weeks in diabetic macular edema, with fewer re-injections than standard anti-VEGF therapy. Effect size was…
Two-year follow-up from an in vivo CRISPR programme shows sustained protein knockdown after a single infusion, with no late safety signals reported. Durability at this…
A generative chemistry pipeline produced a senolytic candidate with a reported 30-fold selectivity margin for senescent over healthy cells in vitro. Animal work is…
Supplementation reliably increased NAD+ blood levels across 12 weeks but produced no statistically significant improvement in muscle strength or walking speed. Secondary…
A selective TORC1 inhibitor entered Phase 2 testing for respiratory infection incidence in older adults. The design follows a previous programme in the same mechanism…
An 82,000-person cohort found that insulin resistance measured in midlife predicted faster epigenetic aging two decades later. The association was strong but…
An off-the-shelf iPSC-derived neuronal therapy moved into a registrational trial after multi-year follow-up showed graft survival and motor improvement. Manufacturing…
A regulatory workshop summary concluded that methylation-based age estimates are not yet acceptable as standalone efficacy endpoints. Clocks may support mechanistic…
A small pilot reported increased naive T-cell output after a hormone-based thymic regeneration protocol. The cohort was tiny and uncontrolled. Immune aging remains one of…
